Details of the Drug

General Information of Drug (ID: DMZW9HA)

Drug Name
Olsalazine
Synonyms Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 302.24
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.2 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.9 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 55.25308 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.07 L/kg [2]
Chemical Identifiers
Formula
C14H10N2O6
IUPAC Name
5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
Canonical SMILES
C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
InChI
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
InChIKey
QQBDLJCYGRGAKP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
22419
ChEBI ID
CHEBI:7770
CAS Number
15722-48-2
DrugBank ID
DB01250
TTD ID
D00KRE
ACDINA ID
D00487

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxidoreductase unspecific (OR) TTPZ7AG NOUNIPROTAC Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Olsalazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Olsalazine caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [5]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Olsalazine and Inotersen. Amyloidosis [5D00] [6]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Olsalazine and Iodipamide. Cholelithiasis [DC11] [7]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [8]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [8]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [8]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Olsalazine and Exjade. Mineral absorption/transport disorder [5C64] [9]
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Gallium nitrate. Mineral excesses [5B91] [8]
Temsirolimus DMS104F Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Temsirolimus. Renal cell carcinoma [2C90] [8]
Salsalate DM13P4C Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Salsalate. Rheumatoid arthritis [FA20] [8]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [8]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Olsalazine and Plazomicin. Urinary tract infection [GC08] [8]
⏷ Show the Full List of 12 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Caramel E00350 61634 Colorant; Flavoring agent
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Olsalazine 250 mg capsule 250 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 ClinicalTrials.gov (NCT00004288) Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis. U.S. National Institutes of Health.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
7 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
8 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
9 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.